Literature DB >> 15353480

The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

James L Riley1, Carl H June.   

Abstract

The CD28 family of receptors (CD28, cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], inducible costimulator [ICOS], program death-1 [PD-1], and B- and T-lymphocyte attenuator [BTLA]) plays a critical role in controlling the adaptive arm of the immune response. While considerable information is available regarding CD28 and CTLA-4, the function of the more recently discovered members of the CD28 family is less well understood. This review will highlight recent findings regarding the CD28 family with special emphasis on effects the CD28 family has on immunopathology, the discovery of costimulatory antibodies with superagonist function, and the status of clinical trials using various strategies to augment or block T-cell costimulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353480     DOI: 10.1182/blood-2004-04-1596

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  104 in total

1.  Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis.

Authors:  Jack T Lin; Emily A Stein; Michael T Wong; Krishna J Kalpathy; Leon L Su; Paul J Utz; William H Robinson; C Garrison Fathman
Journal:  Clin Immunol       Date:  2011-10-01       Impact factor: 3.969

2.  For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.

Authors:  Ma Luo; Christina A Daniuk; Tamsir O Diallo; Rupert E Capina; Joshua Kimani; Charles Wachihi; Makubo Kimani; Thomas Bielawny; Trevor Peterson; Mark G R Mendoza; Sandra Kiazyk; T Blake Ball; Francis A Plummer
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Cutting edge: A role for inside-out signaling in TCR regulation of CD28 ligand binding.

Authors:  Mariano Sanchez-Lockhart; Minsoo Kim; Jim Miller
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

4.  In the absence of its cytosolic domain, the CD28 molecule still contributes to T cell activation.

Authors:  Stéphanie O Morin; Valentin Giroux; Cédric Favre; Yassina Bechah; Nathalie Auphan-Anezin; Romain Roncagalli; Jean-Louis Mège; Daniel Olive; Marie Malissen; Jacques A Nunès
Journal:  Cell Mol Life Sci       Date:  2015-03-01       Impact factor: 9.261

5.  Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines.

Authors:  Wai Kan Chiu; Monchou Fann; Nan-ping Weng
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

6.  BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation.

Authors:  Thang Nguyen; Xikui K Liu; Yongliang Zhang; Chen Dong
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

7.  Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Authors:  Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Hong-Bin Fang; Ling Cai; Stephen Janofsky; Anne Chew; Jan Storek; Gorgun Akpek; Ashraf Badros; Saul Yanovich; Ming T Tan; Elizabeth Veloso; Marcela F Pasetti; Alan Cross; Sunita Philip; Heather Murphy; Rita Bhagat; Zhaohui Zheng; Todd Milliron; Julio Cotte; Andrea Cannon; Bruce L Levine; Robert H Vonderheide; Carl H June
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

8.  A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.

Authors:  Lino C Gonzalez; Kelly M Loyet; Jill Calemine-Fenaux; Vandana Chauhan; Bernd Wranik; Wenjun Ouyang; Dan L Eaton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

Review 9.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Authors:  Xiao-Song Zhong; Maiko Matsushita; Jason Plotkin; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.